TPIV Financials 07/16/2014 15:14:44 TapImmune, In

TPIV Financials 07/16/2014 15:14:44
TapImmune, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 662 1,057 204 290
Sales, General and Admin. 2,648 5,172 3,112 5,182
Non-Recurring Items - - - -
Other - - - -
Operating Income (3,310) (6,229) (3,316) (5,472)
Income From Continuing Operations
Add'l Income/Expense Items (2,223) 58 1,287 1,940
Earnings Before Interest and Tax (5,533) (6,172) (2,637) (3,586)
Interest Expense - - - -
Earnings Before Tax (5,533) (6,172) (2,637) (3,586)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (5,533) (6,172) (2,029) (3,533)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (5,533) (6,172) (2,029) (3,533)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (5,533) (6,172) (2,029) (3,533)